RURodica Usatii

Rodica Usatii

*This is an algorithmically generated author record based on publicly available information.

Rodica Usatii has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rheumatoid arthritis worldwide: inequalities in epidemiology and care

    by Elena Deseatnicova, Valeria Frunze, Rodica Usatii, Liliana Groppa

    Introduction. Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 0.5% of the global population. It represents a major cause of disability, reduced quality of life, and healthcare burden. The prevalence of RA is rising, especially in older populations and in low-income regions. Materials and methods. A systematic literature search was performed in PubMed, ScienceDirect and Google Scholar for articles published between 2000 and 2025. Search terms included "rheumatoid arthritis", "epidemiology", "risk factors", "economic burden", and "healthcare disparities". Results. RA prevalence ranges from 0.3% to 1.0%, with the highest values in Northern Europe (0.8 - 1.0%) and North America (0.7 - 0.9%), and the lowest in Africa (0.1 - 0.3%) and rural Asia (0.2 - 0.4%). Work incapacity has declined in several high-income countries, attributed to earlier diagnosis and the widespread use of disease-modifying antirheumatic drugs. Socio-economic status is a key factor for RA outcomes, with patients in the lowest income groups showing up to 50% higher disability rates. Other risk factors include female sex, HLA-DRB1 alleles, smoking, and environmental exposures. The economic burden is considerable, with direct and indirect costs disproportionately affecting low- and middle-income countries, where RA frequently results in early work disability. Conclusions. RA causes disability and reduces quality of life. Its prevalence is rising worldwide, with higher detection and better outcomes in high-income countries, while low-income countries face underdiagnosis and limited access to modern therapies. Reducing these disparities requires stronger healthcare systems, early diagnosis, and affordable and accessible treatments.

  • Open Access

    Evaluarea dismicrobismului intestinal la pacienții cu sclerodermie sistemică: dezechilibre între flora patogenă și bacteriile comensale

    by Maria Lungu, Svetlana Agachi, Liliana Groppa, Oxana Bujor, Rodica Usatîi, Lilia Taran

    Systemic scleroderma (SS) is a rare autoimmune disease characterized by cutaneous and visceral fibrosis, vascular and immunological involvement. In recent years, the intestinal dysmicrobism has been recognized as an important factor in regulating the immune response and in the development of chronic inflammation. Intestinal dysmicrobism defined as the imbalance between commensal and pathogenic bacteria, has been associated with the severity and activity of the disease in SS. To evaluate the intestinal microbiota profile in patients with systemic scleroderma and to analyze the relationship between the microbiota imbalance and gastrointestinal clinical manifestations. The study included 74 patients with SS (70 women, 4 men, mean age 57.74 ± 1.05 years), hospitalized in 2024-2025 in rheumatology departments in the Republic of Moldova. The limited form was present in 64.86%, and the diffuse form in 35.14%. The status of the intestinal microbiota was assessed bacteriologically from intestinal content samples. Patients with SS showed a significant reduction in commensal bacteria (especially Lactobacillus species, Bifidobacterium spp.) and an increase in opportunistic and pro-inflammatory species (Escherichia coli, Candida spp., Klebsilla pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Citrobacter freundi, Enterobacter cloacae). Dysmicrobism was identified in 85.14% of patients and correlated with the severity of digestive symptoms, especially dysphagia and heartburn. Intestinal dysmicrobism is common (85.14%) in SS and reflects an imbalance between protective and pathogenic flora. These changes may contribute to systemic inflammation and digestive dysfunction, highlighting the importance of evaluating the microbiota as a diagnostic and therapeutic tool.